Shilpa Medicare Announces 1:1 Bonus Issue with Q1FY26 Earnings

The Board of Shilpa Medicare, in its meeting held on Wednesday, August 13, approved the issuance of bonus shares alongside the release of its financial results for the June quarter (Q1FY26).

Shilpa Medicare Bonus Issue Details

Shilpa Medicare has announced a 1:1 bonus issue, entitling eligible shareholders to receive one bonus share for every share held. This move marks the company’s first bonus issue in over 12 years — the last such distribution was made in 2013, when shareholders received one bonus share for every two shares held.

The record date for the bonus issue has been set as September 26, 2025, subject to shareholder approval. Shilpa Medicare aims to credit the bonus shares to shareholders' accounts within the following two months.

Shilpa Medicare Q1 FY26 Earnings Highlights

For the quarter ended June 2025, Shilpa Medicare reported a significant jump in profitability and operational performance:

• Net profit surged to ₹46.8 crore, up sharply from ₹14 crore in the same quarter last year.
• Revenue rose 9.9% year-on-year to ₹321.5 crore, compared to ₹292.5 crore in the June 2024 quarter.
• EBITDA stood at ₹91.7 crore, reflecting a 25% increase over the previous year.
• EBITDA margins improved by 350 basis points, expanding to 28.5%, up from 25% last year.

Also Read: HPCL Shares to Trade Ex-Date on Aug 14: Final Dividend of ₹10.50

Commenting on the Q1FY26 performance, Mr. Vishnukant Bhutada, Managing Director. Said, “The first quarter of FY26 demonstrated steady progress and strong execution of our strategic priorities. Our partner successfully launched our second NDA in the U.S.—Bortezomib RTU— reinforcing our R&D-driven approach and delivering differentiated products that enhance ease of administration.

Pemetrexed also gained momentum in the U.S., while Nilotinib continued to expand its presence in the EU. Additionally, we achieved a historic milestone with NorUDCA’s approval, making Shilpa the first global company approved for NAFLD treatment. These approvals, along with our robust NDA pipeline, position us for sustained future growth.

Our API division(including captive) has reported growth of ~25% YoY basis. New product launches, CDMO expansion, expanded capacities, and an improved product mix favouring regulated markets, are expected to drive further growth for FY26.”

Shilpa Medicare Share Price Performance

Reacting to the announcement, Shilpa Medicare shares soared over 2%, reaching a day high of ₹944.95 at 10:00 AM after opening at ₹944.95 on BSE. Despite the recent uptick, the stock has gained 12% year-to-date in 2025 and has delivered a 45% return over the past 5 years.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.